Clinical trial NCT04721600: Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
Official title: Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Laxity
Lead sponsor: InMode MD Ltd.
Sponsor class: INDUSTRY
First posted: 2021-01-22
Enrollment: 15
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance

Detailed description: The aim of the study is to evaluate the safety, efficacy, patient comfort, and patient satisfaction after Evoke treatment

Eligibility criteria: Inclusion Criteria:

* - Signed informed consent to participate in the study.
* Female and male subjects, 35 and 75 years of age at the time of enrolment
* If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
* In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
* General good health confirmed by medical history and skin examination of the treated area.
* Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
* The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period.

Exclusion Criteria:

* - Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.
* Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance, unless deep enough in the periostal plane.
* Current or history of skin cancer, or current condition of any other type of cancer, or premalignant moles.
* Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
* Pregnancy and nursing.
* Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
* Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
* Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.
* Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
* History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
* History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
* Any surgery in treated area within 3 months prior to treatment.
* Six months delay is required if other recent treatments like light, CO2 laser or RF were performed on the same area.
* Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
* As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient

Primary outcomes:
measure: Percentage of Participants With Baseline and 6 Month Face Photographs Correctly Identified by Two Blind Evaluators
timeFrame: 6 months
Secondary outcomes:
measure: Investigator Assessment of the Skin Appearance
timeFrame: month 6
measure: Subject Assessment of Change and Satisfaction With the Procedure
timeFrame: month 6
Other outcomes:
Locations:
city: Chestnut Hill
country: United States
facility: Skincare physicians
state: Massachusetts
Study officials:
affiliation: Skincare physicians
name: Jeffrey Dover, MD
role: PRINCIPAL_INVESTIGATOR
References: